NSE ScannerPharmaceuticals · Biotechnology · NSE: FABTECH · data 2026-10-31
Fabtech Technologies Limited
In plain words
Price: 52.0% below its 52-week high of ₹258.
Delivery: 50.3% of traded shares were kept for delivery over the last 10 sessions, against 52.2% over the last 60.
Latest results: a net profit of ₹15 cr for the quarter ended Sept 2026 (-46.6% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹388 cr |
| Net profit (last 12 months) | ₹36 cr |
| Sales growth, 3 years (yearly) | 29.2% |
| Profit growth, 3 years (yearly) | 20.8% |
At a glance
Promoters 69.0%, pledged 0.0%, institutions 2.5%.
P/E 14.1, P/B 1.3, dividend yield 0.5%. Price relative to earnings and book value (low is cheaper, not better).
ROE 12.9%, ROCE 9.1%, operating margin 5.1%: how much profit it earns on the money it uses.
Debt/equity 0.17, Profit growth 20.8% and sales growth 29.2% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Profit grew 20.8% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q2 FY27)
FABTECH Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹92.09 crore, down 24.2% YoY and up 22.8% QoQ.
Net profit was ₹15.02 crore, down 46.6% YoY and up 256.8% QoQ.
Operating margin was 11% (25.1% a year ago).
EPS was ₹3.38, down 46.6% YoY and up 255.8% QoQ.
FABTECH के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹92.09 करोड़; पिछले साल की तुलना में 24.2% की गिरावट, पिछली तिमाही की तुलना में 22.8% की बढ़त।
शुद्ध मुनाफ़ा: ₹15.02 करोड़; पिछले साल की तुलना में 46.6% की गिरावट, पिछली तिमाही की तुलना में 256.8% की बढ़त।
ऑपरेटिंग मार्जिन: 11% (एक साल पहले 25.1%)।
EPS: ₹3.38; पिछले साल की तुलना में 46.6% की गिरावट, पिछली तिमाही की तुलना में 255.8% की बढ़त।
FABTECHના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹92.09 કરોડ; ગયા વર્ષની સરખામણીએ 24.2% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 22.8% વધારો.
ચોખ્ખો નફો: ₹15.02 કરોડ; ગયા વર્ષની સરખામણીએ 46.6% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 256.8% વધારો.
ઓપરેટિંગ માર્જિન: 11% (એક વર્ષ પહેલાં 25.1%).
EPS: ₹3.38; ગયા વર્ષની સરખામણીએ 46.6% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 255.8% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
20/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 15/30: Delivery 45.1% over the last 20 sessions vs 52.7% in the 40 before (0.86x); shares delivered per day 1.75x usual; 2 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 28 Oct 26Results Q2 FY27 results: profit −46.6% YoY -3.7% next session
- 17 Aug 26Dividend Dividend ₹0.6 (ex-date) -1.4% next session
- 24 Jul 26Results Q1 FY27 results: turned to profit vs a year ago +0.2% next session
- 27 Apr 26Results Q4 FY26 results: net profit ₹22.1 cr +11.9% next session
- 2 Feb 26Results Q3 FY26 results: net profit −₹5.7 cr -5.4% next session
- 28 Oct 25Results Q2 FY26 results: net profit ₹28.1 cr +4.9% next session
- 28 Oct 25Results Q1 FY26 results: net profit −₹6.1 cr +4.9% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹92 cr | ₹15 cr | -46.6% | 11.0% | 3.38 |
| Jun 2026 | ₹75 cr | ₹4 cr | — | 5.7% | 0.95 |
| Mar 2026 | ₹159 cr | ₹22 cr | — | 14.0% | 5.75 |
| Dec 2025 | ₹63 cr | ₹-6 cr | — | -18.3% | -1.56 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 69.03% | 68.94% | 68.94% | 68.94% |
| Foreign institutions (FII) | 0.02% | 0.02% | 0.08% | 0.03% |
| Domestic institutions (DII) | 2.45% | 2.45% | 2.15% | 1.99% |
| Mutual funds | 0.00% | 0.00% | 0.00% | — |
| Retail investors | 11.58% | 12.58% | 11.30% | 13.64% |
| Number of shareholders | 28,336 | 29,408 | 28,620 | 31,755 |
Common questions
What was Fabtech Technologies Limited's latest quarterly profit?
Fabtech Technologies Limited reported a net profit of ₹15 cr for the quarter ended Sept 2026 (-46.6% on the same quarter a year earlier), on revenue of ₹92 cr.
How much do promoters hold in Fabtech Technologies Limited?
Promoters held 69.03% of Fabtech Technologies Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Fabtech Technologies Limited debt-free?
Its latest reported debt-to-equity ratio is 0.17.
What is Fabtech Technologies Limited's P/E ratio?
About 14.1, based on the last 12 months' earnings and a price of ₹123.9 (data 2026-10-31).
What is the 52-week high and low of Fabtech Technologies Limited?
The 52-week high is ₹258 and the 52-week low is ₹115.1.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Fabtech Technologies Limited | ₹123.9 | ₹547 cr | 14.1 | 1.3 | 12.9% | 9.1% | 0.17 | -48.7% |
| Anthem Biosciences Limited | ₹828.8 | ₹46,685 cr | 81.7 | — | 21.7% | 26% | 0.02 | +13.6% |
| Rubicon Research Limited | ₹1,610.5 | ₹26,650 cr | 92.7 | — | 27% | 32.4% | 0.24 | +168.0% |
| Akums Drugs and Pharmaceuticals Limited | ₹731.7 | ₹11,520 cr | 38.4 | — | 8% | 9.8% | 0.05 | +55.4% |
| Fermenta Biotech Ltd | ₹417.55 | ₹1,229 cr | 20.2 | — | 18.7% | 20.8% | 0.28 | +34.7% |
| Haleos Labs Ltd. | ₹1,394.4 | ₹411 cr | 26.7 | — | 8.4% | 10.4% | 0.52 | +22.2% |
Compare FABTECH with ANTHEM in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open FABTECH in NSE Scanner →